

BAB 5

KESIMPULAN DAN SARAN

5.1 Kesimpulan

Berdasarkan hasil penelitian tentang studi penggunaan kombinasi oral antidiabetes dengan insulin pada pasien diabetes melitus tipe 2 periode Januari 2017 – Desember 2017 di Paviliun III rawat inap RUMKITAL Dr. Ramelan Surabaya dapat disimpulkan sebagai berikut :

- a. Terapi kombinasi 1 OAD dengan 1 Insulin paling banyak adalah Metformin (3x500 mg) PO+Novorapid® (3x8-10 ui) SC. Terapi kombinasi 1 jenis OAD dengan 2 jenis Insulin paling banyak adalah Metformin (3x500 mg) PO+Novorapid® (3x4-8ui) SC+Levemir® (0-0-10 ui). Terapi kombinasi 1 jenis OAD dengan 3 jenis Insulin paling banyak adalah Glimepirid (1-0-1) PO+Novorapid® (3x8ui) SC+Levemir® (0-0-18ui) SC+Apidra® (3x10 ui) IV.
- b. Penggunaan oral antidiabetes (OAD) yang paling banyak digunakan adalah Metformin. Sedangkan penggunaan Insulin yang paling banyak digunakan adalah *rapid acting insulin* yakni Novorapid®.

5.2 Saran

- a. Penulisan rekam medik pasien sebaiknya ditulis dengan lengkap dan jelas sehingga tidak mempersulit saat mengambil data yang akurat pada penelitian retrospektif.
- b. Terapi diabetes melitus pada pasien diabetes melitus tipe 2 sangat kompleks, sehingga diperlukan kerjasama antar profesi kesehatan termasuk apoteker.

DAFTAR PUSTAKA

- AACE., 2013, American Association of Clinical Endocrinologists Comprehensive Diabetes Management Algoritmha 2013 Consensus Statement, *Endocrine Practice*, **19(2)** : 3-28.
- Abougalambou, S.S.I., Abougalambou, A.S., Sulaiman, S.A.S. and Hassali, M.A., 2012. Prevalence of hypertension, control of blood pressure and treatment in hypertensive with type 2 diabetes in Hospital University Sains Malaysia, *Diabetes & metabolic syndrome*, **5(3)**: 115–9.
- Ali, M. A., 2015, *A New Approach in Type 2 Diabetes Melitus Treatment: Evaluation of The Beneficial Effect of L-cysteine in The Treatment of Type 2 Diabetes Melitus*, Anchor Academic Publishing, Hamburg, Germany.
- Almasdy, D., Sari, D.P., Suharti, Darwin, D. dan Kurniasih, N., 2015, Evaluasi Penggunaan Obat Antidiabetik pada Pasien Diabetes Melitus Tipe-2 di Suatu Rumah Sakit Pemerintah Kota Padang - Sumatera Barat, *Jurnal Sains Farmasi dan Klinis*, **2(1)**: 104-110.
- American Diabetes Association, 2013, Standart of Medical Care in Diabetes, *Diabetes Care Journal*, **36 (1)**: 11-65.
- American Diabetes Association, 2014, Standart of Medical Care in Diabetes, *Diabetes Care Journal*, **37 (1)**: 81-90.
- American Diabetes Association, 2015, Standart of Medical Care in Diabetes, *Diabetes Care Journal*, **38 (1)**: 1-93.
- Anderson, P. O., Knoben, J. E. and Troutman, W. G., 2002, *Handbook of Clinical Drug Data*, 10th Edition. The McGraw-Hill Companies, New York.
- Arikunto, S., 2006, *Prosedur Penelitian Suatu Pendekatan Praktik*, Rineka Cipta, Jakarta.
- Awad, N., Langi, Y. dan Pandelaki, K. 2013, Gambaran Faktor Resiko Diabetes Mellitus Tipe 2 Di Poliklinik Endokrin Bagian/SMF FK-USRAD RSU Prof. Dr. R. D. Kandou Manado. *Jurnal e-Biomedik (Ebm)*, **1(1)**:45-49.

- Baso A.A.Y., Umar, H. dan Manggau M.A., 2014, ‘Pengaruh terapi terhadap pasien diabetes melitus tipe 2 preoperatif’, *Skripsi*, Sarjana Kedokteran, Universitas Hasanuddin, Makassar.
- Burnham, T.H., 2000, *Drug Facts and Comparisons* 55th edition, A Wolter Kluwer Company, St. Louis.
- Champe, P.C., 2013, *Farmakologi Ulasan Bergambar* Edisi 4, EGC, Jakarta
- Chang, C.L.T., Lin Y., Bartolome A.P., Chen Y.C., Chiu S.C., and Yang W.C., 2013, *Herbal Therapies for Type 2 Diabetes Mellitus: Chemistry, Biology, and Potential Application of Selected Plants and Compounds. J Evid Based Complementary Altern Med*, **13**:1-33.
- Codario, R. A., 2005, *Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome*, Humana Press, Totowa, New Jersey.
- Davis, S.N. and Granner,D.K., 2001, ‘Insulin Oral Hypoglycemic Agents and the Pharmacology of the Endocrine Pancreas’, in Hardman, J.G. and Limbird, L.E., *Goodman and Gilman’s The Pharmacology Basis of Therapeutics*, 10th edition, McGraw-Hill Companies, Inc, New York, p. 1694-1701.
- Departemen Kesehatan RI., 2005, *Pharmaceutical Care untuk Penyakit Diabetes Melitus*, Jakarta: Departemen Kesehatan Republik Indonesia.
- Fatimah, R.N., 2015, Diabetes Melitus Tipe 2, *J Majority*, **4(5)**: 93-101.
- Fujita, Y. and Inagaki, N., 2014, Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. *J Diabetes Invest.* **5**:265–75.
- Fung, J.L. and Feingold, K.R.,1995, ‘Disorder of the Endocrine Pancreas’, in McPhee, S.J., Lingappa, V.R., Ganoong, W.F. and Lange, J.D., *Pathophysiology of Disease An Introduction to Clinical Medicine*, 1st ed.,Apletion & Lange, Stamford, p 380-389.
- Funk, J.L., 2014, ‘Disorder of The Endocrine Pancreas’, in Hammer G.D & MacPhee S.J., *Pathophysiology of Disease An Introduction to*

Clinical Medicine Seventh Edition, Mc Graw Hill Education Lange, New York.

Ganoong, W.F., 1997, *Review of Medical Physiology*, 18th ed.,Prentice-Hall International, Inc., San Francisco.

Haeria, 2009, Pelayanan Kefarmasian Dalam Penatalaksanaan Diabetes Melitus, *Jurnal Kesehatan*, **2(4)**, 19-26.

Handoko, T., dan Suharto. B., 1995, *Insulin Glukagon dan Anti Diabetik Dalam Farmakologi dan Terapi*, Edisi IV, Gaya Baru, Jakarta.

Inayah, Hamidy, M.Y. dan Yuki, R.P.R., 2016, Pola Penggunaan Insulin Pada Pasien Diabetes Melitus Tipe 2 Rawat Inap Di Rumah Sakit X Pekanbaru Tahun 2014, *Jurnal Ilmu Kedokteran*, **10(1)**: 38-43.

International Diabetes Federation., 2013, *International Diabetes Federation Diabetes Atlas* 6th Ed, Belgium: International Diabetes Federation.

Irawan, D., 2010. ‘Prevalensi dan Faktor Risiko Kejadian Diabetes Melitus Tipe 2 di Daerah Urban Indonesia (Analisa Data Sekunder Riskesdas 2007)’, *Thesis*, Universitas Indonesia, Depok.

Irons, B., 2013. New Pharmacotherapies for Type 2 Diabetes. Diakses pada 5 Juli 2013, https://www.accp.com/docs/bookstore/psap/p13b1_m1ch.pdf.

Jerums, G., Ekinci E., Premaratne E., Baker S., Panagiotopoulos, S., MacIsaac, R., 2015. Diabetic nephropathy. In DeFronzo R. A., Ferrannini E., Zimmet P., Alberti George M.M., *Diabetes Mellitus Fourth Edition*. Wiley Blackewell, Oxford.

Kalra, S., 2014, Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology, *Diabetes Ther*, **5**:355–366.

Kasichayanula, S., Liu, X., LaCreta, F., Griffen, S., Boulton, D., 2014, Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. *Clin Pharmacokinet*, **53**:17–27.

Katzung, B. G., 2002, *Farmakologi Dasar dan Klinik* Edisi II, Salemba Medika, Jakarta.

Kawano T., 2014. ‘A Current Overview of Diabetic Neuropathy-Mechanisms, Symptoms, Diagnosis, and Treatment’, in Da Silva, P.A., *Peripheral Neuropathy*, IntechOpen, London, pp: 89-99.

Kendall, D.M., 2005, Review: Short Acting Insulin Analogues Reduce Glycosylated Hemoglobin More than Regular Human Insulin but only in Adults with Type 1 Diabetes, *ACP Journal Club*, **142(2)** : 62-63.

Kennedy M and Masharani U., 2015. ‘Pancreatic Hormone and Antidiabetic Drugs’, in Katzung G.B. & Trevor A.J., *Basic and Clinical Pharmacology*. 13th ed., Mc Graw Hill Medical, New York.

Kennedy, M. S. N., 2012. ‘Pancreatic Hormones & Antidiabetic Drugs’, in Katzung, B.G., Masters, S.B., and Trevor, A.J., *Basic & Clinical Pharmacology*, 12th Ed.,The McGraw-Hill Companies, New York, Section VII, Chapter 41.

Kosti, M. dan Kanakari, M., 2012, Education and diabetes mellitus, *Health Science Journal*, **6(4)**: 654-662.

Kroon, L. A. and Williams, C., 2013, ‘Diabetes Melitus’, in Alldredge, B.K., Corelli, R.L., Ernst, M.E., Guglielmo, B.J., Jacobson P.A., Kradjan, W.A., and Williams, B.R., 2013, *Applied Therapeutics The Clinical Use of Drugs*, 10th ed., Lippincott Williams & Wilkins, Philadelphia.

Kuritzky, L., 2006, Addition of Basal Insulin to Oral Antidiabetic Agents: A Goal Directed Approach to Type 2 Diabetes Therapy. *MedGenMed*, **8(4)**: 34.

Kurniawan, 2010, Diabetes Melitus Tipe 2 pada Usia Lanjut, *Majalah Kedokteran Indonesia*, **60 (12)**: 576-584.

Lathifah, N.L., 2017, Hubungan Durasi Penyakit Dan Kadar Gula Darah Dengan Keluhan Subyektif Penderita Diabetes Melitus, *Jurnal Berkala Epidemiologi*, **5(2)**: 231-239.

- Marwan, Ratiangsih, R. dan Jaya, A.I., 2015, Optimal Kontrol Model Dinamik Glukosa, Insulin, Massa Sel- β , dan Reseptor Insulin pada Penyakit Diabetes Melitus Tipe 2 Dengan Pengaturan Aktivitas Fisik Dan Pola Makan Pendahuluan, *Jurnal Ilmiah Matematika dan Terapan*, **12(1)**: 23-34.
- Metha, D.K., 2002, *British National Formulary* 44th ed., British Medical Association and the Royal Pharmaceutical Society of Great Britain, London.
- Ministry of Public Health and Sanitation., 2010, *National Clinical Guidelines for Management of Diabetes Mellitus First Edition*, Kenya: Ministry of Public Health and Sanitation.
- Mogensen, U. M., Andersson, C., Fosbol, E. L., Schramm, T. K., Vaag A., Scheller, N. M., Torp-Pedersen, C., Gislason, G., and Kober, L., 2015, Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study, *Diabetologia*, **58**:50–58.
- Mudaliar, S., Henry, R. and Boden, G., 2014, Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin, *Diabetes Technol Ther.* **16**:137–44.
- National Institute of Diabetes and Digestive and Kidney Diseases., 2011, *Cause Of Diabetes*, USA: Department Of Health & Human Services.
- Ndraha, S., 2014, Diabetes Melitus Tipe 2 dan Tatalaksana terkini, *Medicinus*, **27(2)**, 9-16.
- Paulus, 2012, ‘Gambaran Tingkat Pengetahuan Faktor Risiko Diabetes Melitus Pada Mahasiswa Fakultas Ekonomi Universitas Indonesia’, *Skripsi*, Sarjana Keperawatan, Universitas Indonesia, Depok.
- Perkeni., 2006, *Konsesus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*, Jakarta: Pengurus Besar Perkumpulan Endokrinologi Indonesia.
- Perkeni., 2011, *Konsesus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*, Jakarta: Pengurus Besar Perkumpulan Endokrinologi Indonesia.

Perkeni., 2015, *Konsesus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*, Jakarta: Pengurus Besar Perkumpulan Endokrinologi Indonesia.

Powers, A. C., 2008. ‘Diabetes Mellitus’, in Fauci, A.S., Braunwald, E., Kasper, D.L., Hauser, S.L., Longo, D.L., Jameson J.L., and Loscalzo J., *Harrison’s Principles of Internal Medicine 17th Ed.*, McGraw Hill, New York.

Pujihastuti, A., 2008, ‘Analisis Tingkat Kepuasan Pasien Askeskin, Askes PNS, Umum pada Pelayanan Loket Pendaftaran Rawat Jalan di RSUD Kabupaten Karanganyar’, *Skripsi*, Sarjana Kesehatan Masyarakat, Universitas Muhammadiyah Surakarta

Putra, I.M.A.S., Udayani, N.N.W. dan Meriyani, H., 2017, Analisis Efektivitas Biaya Penggunaan Terapi Insulin Dan Insulin Kombinasi Pada Pasien Diabetes Mellitus Tipe II Rawat Jalan Di RSUP Sanglah, *Medicamento*, **3(2)**: 103-109.

Rahayu, E.T., Arjana, A.Z., Juwariyah, Mulyaningrum, U. dan Irfan, R.M., 2017, Profil Koagulasi Pasien Penderita Diabetes Mellitus Di Rs X, Kebumen, Jawa Tengah, *Biomedika*, **9(1)**: 44-49.

Ray, S., Pramanik, S., and Ghosh S., 2016, Combination Treatment of Oral Agents and Insulin in Type 2 Diabetes: A Narrative Review, *International Journal of Diabetes & Metabolic Disorders*, **1(1)**: 1-7.

Rorsman, P., 2005, Insulin secretion: function and therapy of pancreatic beta-cells in diabetes, *The British Journal of Diabetes and Vascular Disease*, **5(4)**:187-191.

Sari, F.D., Inayah dan Hamidy, M.Y., 2016, Pola Penggunaan Obat Anti Hiperglikemik Oral Pada Pasien Diabetes Melitus Tipe 2 Rawat Inap Di Rumah Sakit X Pekanbaru Tahun 2014, *Jom FK*, **3(1)**: 1-14

Sarwono, J., 2006, *Metode Penelitian Kuantitatif dan Kualitatif*, Graha Ilmu, Yogyakarta.

Setter, S.M., White, J.R., and Campbell, R.K., 2000, ‘Diabetes’, in Herfindal, E.T. and Guorley, D.R., *Textbook of Therapeutics Drug and Disease Management*, 7th ed., Lippincott Williams & Wilkins, Philadelphia, p: 378-396.

- Sunjaya, I.N., 2009, Pola Konsumsi Makanan Tradisional Bali sebagai Faktor Risiko Diabetes Melitus Tipe 2 di Tabanan, *Jurnal Skala Husada*, **6(1)**: 75-81.
- Tandra, H., 2008, *Segala Sesuatu yang Harus Anda Ketahui Tentang Diabetes*. Gramedia Pustaka Utama, Jakarta.
- Triplitt, C.L., Reasner, C. A., and Isley, W. L., 2011. ‘Diabetes Mellitus’, in DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G. and Posey, L.M., *Pharmacotherapy: A Pathophysiologic Approach*, 8th Ed., The McGraw-Hill Companies, New York, Section 8, Chapter 77.
- Trisnawati, S.K., dan Setyorogo, S., 2013, Faktor Risiko Kejadian Diabetes Melitus Tipe II Di Puskesmas Kecamatan Cengkareng Jakarta Barat Tahun 2012, *Jurnal Ilmiah Kesehatan*, **5(1)**: 6-11.
- Wihardiyanti, R.R., Subagio P.B. dan Fajrin, F.A., 2015, Efektivitas Penggunaan Insulin pada Penderita Diabetes Melitus dengan Kehamilan di Rawat Inap RSD dr. Soebandi Jember Tahun 2012-2013, *e-Jurnal Pustaka Kesehatan*, **3(3)**: 430-435.
- Wilcox, 2005, Insulin and Insulin Resistance, *Clin Biochem Rev*, **26(2)**: 19-39.
- Wilson, D.D., 2008, *Manual of Laboratory and Diagnostic Test*, The McGraw-Hill Companies, New York.
- Yulianti, S.R., Mukaddas, A. dan Faustine, I., 2014, Profil Pengobatan Pasien Diabetes Mellitus Tipe 2 Di Instalasi Rawat Inap Rsud Undata Palu Tahun 2012, *Online Jurnal of Natural Science*, **3(1)**: 40-46.